← Eichor
Study identifier: NCT05762991 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion

Condition: Helicobacter Pylori Infection · Premalignant Lesion  ·  Sponsor: National Taiwan University Hospital

PhaseN/A
Planned participants6000
Who can joinAll sexes, 20 Years to 80 Years
Healthy volunteersNo

About this study

The aim of this study is to evaluate the impact of artificial intelligence (AI) assistance during routine upper endoscopy on gastric cancer-specific mortality. We hypothesize that AI-assisted endoscopic interpretation can further reduce gastric cancer-related mortality through two mechanisms: (1) improved detection of H. pylori infection, facilitating timely eradication therapy and subsequent prevention of gastric carcinogenesis; and (2) earlier identification of premalignant gastric conditions, enabling appropriate surveillance endoscopy and earlier detection of gastric cancer. The primary endpoint is gastric cancer-specific mortality.

This description comes directly from the study's public registry record.

Talk to the study team

Yi-Chia Lee, MD, PhD  ·  886-2-23123456  ·  yichialee@ntu.edu.tw

Tsung-Hsien Chiang, MD,PhD  ·  886-2-23123456  ·  thchiang@ntu.edu.tw

Always discuss trial participation with your own doctor first.

Locations (1)

Yi-Chia LeeTaipei, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05762991